Aim: To search for novel inhibitors of human polo-like kinase 1 (Plk1), which plays important roles in various aspects of mitotic progression and is believed as a promising anti-cancer drug target, and further investigate the potential inhibition mechanism of active compounds against Plk1, thus developing potent anti-tumor lead compounds. Methods: Surface plasmon resonance (SPR) technology-based assay and enzymatic inhibition assay were used to screen Plk1 inhibitors. Sulphorhodamine B (SRB)-based assay, flow cytometry, confocal microscopy and Western blotting were used to further identify the potent Plk1 inhibitor. To investigate the inhibitory mechanism of the active compound against Plk1, enzymatic inhibition assay, SPR and yeast two-hybrid technology-based assays were used. Results: Aristolactam AIIIa was identified as a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD) which is another efficient tactic for exploring Plk1 inhibitors. Further studies indicated that it could block the proliferations of HeLa, A549, HGC and the HCT-8/V cells (clinical Navelbine-resistant cancer cell), induce mitotic arrest of HeLa cells at G 2 /M phase with spindle abnormalities and promote apoptosis in HeLa cells. The results from SPR and yeast two-hybrid technology-based assays suggested that it could target both the catalytic domain of Plk1 (CD) and PBD and enhance the CD/PBD interaction. Conclusion: Our current work is expected to shed light on the potential anti-tumor mechanism of Aristolactam AIIIa, and this natural product might be possibly used as a lead compound for further developing anti-tumor drugs.
Introduction
Polo-like kinases (Plks) belong to a family of Ser/Thr protein kinases and play a variety of roles in cell cycle progression [1] . To date, four members of this family have been identified in mammalian cells, termed as Plk1, Plk2 (SNK), Plk3 (PRK/ FNK), and Plk4 (SAK) [2] [3] [4] [5] [6] , of which Plk1 is the best characterized. It has been discovered that Plk1 functions importantly in numerous aspects of mitotic progression, including controlling entry into mitosis through the activation of the cdc2/ cyclinB complex [7] , centrosome maturation [8] , bipolar spindle formation [8] , sister chromatid separation [9] , anaphase promot-covery of anti-tumor agents. Structurally, Plks are homologous and contain two conserved domains, the N-terminal catalytic kinase domain (CD) and the C-terminal polo box domain (PBD) that is composed of so-called polo boxes. The PBD exhibits a critical role in the regulation of Plk1's kinase activity and the subcellular localization of Plk1 [16] . It has been reported that Plk1 interacts, through its PBD, with certain serine/threonine-phosphorylated proteins localized at particular mitotic apparatuses, and binding of the PBD to the primed phosphorylation sites not only serves for targeting the kinase domain to substrates but also simultaneously activates the kinase domain by relieving the inhibitory intramolecular interaction [17] . Therefore, in addition to blocking the ATP-binding or the substrate-binding site, targeting the PBD is also considered as another efficient tactic for the exploration of Plk1 inhibitors.
The first published small molecular Plk1 inhibitor was scytonemin, a natural marine product isolated from cyanobacteria [18, 19] , which is a micromolar non-specific ATP competitor. The pharmacophore ON01910 was a non-ATP competitive inhibitor of Plk1, which was probably a substrate-competitive inhibitor of recombinant casein and CDC25C [20] . The first small molecule inhibitor targeting the PBD was reported recently [21] , which could interfere with Plk1 intracellular localization by inhibiting the function of the PBD.
In the current work, by random screening against our inhouse natural product library, we discovered that the natural product Aristolactam AIIIa ( Figure 1A ), an Aristolactam derivative [22] , functions as a new type of ligand targeting the PBD. It could inhibit the proliferation of cancer cells and induce apoptosis and the mitotic arrest at G 2 /M phase with spindle abnormalities. Different from the published Plk1 inhibitors, this natural product not only targeted both the CD and PBD domains, but also enhanced the CD/PBD interaction. Our findings might help to shed light on the possible mechanism of the Aristolactams inhibition against cancer cell proliferation [23, 24] , and Aristolactam AIIIa might be used as a potential lead compound for further research.
Materials and methods

Plasmid construction
The PBD (residues 326-603 of Plk1) and the catalytic domain of Plk1 (CD, residues 1-370 of Plk1) were amplified by PCR from pUC18-Plk1 (synthesized by Shanghai Sangon Biological Engineering Technology & Services Co, Ltd, Shanghai, China), and then subcloned into the vector pGEX4T-1 and pFastBacHTb, respectively. For the yeast two-hybrid assay, the DNA fragment encoding the PBD was digested with EcoR I and Xho I (NEB) from the pGEX4T-1-PBD plasmid and then cloned into the pGADT7 vector. Similarly, the catalytic domain of Plk1 was cloned into the pGBKT7 vector from pFsatBacHTA-CD. For overexpression, the PBD and CD were amplified by PCR from pUC18-Plk1 and then subcloned into the vector pCDNA3.1a, respectively.
Protein preparation
By using pGEX4T-1-PBD as the expression plasmid, the recombinant protein GST-tagged PBD was expressed in E coli BL21 (DE3) cells and purified by glutathione-affinity chromatography. The GST tag was cleaved on column with thrombin (Pharmacia) and the native PBD was obtained by gel filtration. The His-tagged catalytic domain of Plk1 was expressed in TN insect cells (TN-5B1-4, Trichoplusia Ni) using standard baculovirus expression protocols and purified with Ni-NTA affinity chromatography.
In vitro enzymatic assays of the full-length Plk1 and its catalytic domain The enzymatic assays of Plk1 and its catalytic domain were performed using the Cyclex Plk1 assay kit/inhibitor screening kit (Cyclex Co, Japan). Kinase inhibition experiments were carried out according to the protocol provided by the manufacturer. Plates were precoated with the substrate termed recombinant Protein-X, which contains a threonine residue that can be phosphorylated by Plk1. The detector antibody specifically detects the phosphorylated threonine on Protein-X. During the assay, Plk1 or its catalytic domain was dissolved in 10 µL kinase buffer and mixed with 10 µL of compound solution at different concentrations (prepared by diluting 1 µL of DMSO mother liquor into 9 µL kinase buffer). The mixture was finally added to 80 µL of kinase buffer containing 50 µmol/L ATP. After pre-incubation at 4 °C for 80 min, the plates were incubated at 30 °C for 30 min, and the wells were washed five times with 1×wash buffer provided by the manufacturer. Subsequently, 100 µL of anti-phospho-threonine polyclonal antibody (PPT-07) was added to each well and incubated at room temperature for 30 min. The wells were washed five times as described above and incubated with 100 µL of HRPconjugated anti-rabbit IgG. Following a 30-min incubation at room temperature, the wells were washed five times and incubated with 100 µL of a chromogenic substrate reagent for 5 min. The reaction was terminated with 100 µL stop solution, and the amount of phosphorylated substrate was determined by measuring the absorbance at dual wavelengths of 450/540 nm.
Immunoprecipitation
For Plk1 immunoprecipitation, HeLa cells (4×10
6 cells/well) were seeded on 10-mm dish and incubated overnight. After incubation with nocodazole (5 µg/mL) for 12 h, the cells were lysed with 500 µL cold lysis buffer containing a protease inhibitor cocktail. The cell lysate was treated with 500 µL of lysis buffer containing 10 µL of a prepared protein A/G bead slurry 1 h at 4 °C and then centrifuged at 13 000 r/min for 15 min at 4 °C. The supernatant was carefully collected without disturbing the pellet and transferred to a clean tube, followed by incubation with 10 µL of Plk1 antibody (1:50, 35-306 aa, Abcam) overnight. After incubated with 20 µL pre-cleared protein A/G bead slurry at 4 °C for 3 h on a rotator, the mixture was spun at 13 000 r/min for 2 min at 4 °C. The supernatant was carefully removed and the beads were washed twice with 50 µL kinase buffer. After the final wash, the agarose beads were resuspended in 50 µL kinase buffer and mixed gently. The catalytic domain of Plk1 (residues 1-370 of Plk1) that was transiently transfected into 293T cells for 48 h was immunoprecipitated with an anti-myc antibody (1:400, Invitrogen).
Sulfphorhodamine B-based assay for cell proliferation The quantitative sulphorhodamine B (SRB) colorimetric assay [25] was used for determining the inhibition of Aristolactam AIIIa against HGC, A549, HeLa, and HCT-8/V cancer cells. Cells were seeded onto a 96-well plate with 5000 cells per well and incubated at 37 °C for 24 h. The cells were treated with increasing concentrations of Aristolactam AIIIa for another 72 h, fixed with 10% trichloracetic acid for 1 h at 4 °C, air-dried, and then stained at room temperature for 20 min with 4 mg/mL SRB solution. Cells were subsequently washed with 1% acetic acid five times and dissolved in 150 µL of 10 mmol/L Tris buffer. The cell viability was presented as absorbance at 515 nm (Benchmark Plus TM microplate spectrophotometer, BIO-RAD) and averaged from three replicates. The values were obtained from three independent experiments. NVB (Navelbine) and DMSO were used as positive and negative controls, respectively. All cell culture reagents were purchased from Gibco.
Analysis of cell cycle progression
HeLa cells (3×10 4 cells/well) were seeded onto 6-well plates and incubated overnight. After being incubated with Aristolactam AIIIa (10 µmol/L) for 24 or 48 h, the adherent cells were detached with trypsin, and the floating cells were collected by centrifugation at 600×g for 10 min. The cells were washed twice with PBS, fixed in 75% ethanol-PBS at 4 °C for 2 h, and then collected by centrifugation. Cells were resuspended with 500 µL PBS containing 100 mg/mL RNase A and incubated for 30 min at 37 °C, followed by filtration and staining with 0.5 mg/mL propidium iodide (PI) for 1 h. The suspensions were then analyzed by Becton Dichinson FACScan (BD Biosciences, San Jose, CA). The percentage of cells in the G 0 /G 1 , G 2 /M phases of the cell cycle was determined by the DNA contents.
Confocal microscopy
HeLa cells grown on glass coverslips were washed with PBS and fixed in 4% paraformaldehyde. After washed with PBS for 5 min, the fixed cells were treated with PBS containing 1% Triton at room temperature for 10 min and then washed with PBS containing 0.02% Tween 20 for 5 min. To image the spindle apparatus, the fixed cells were incubated with a FITC-conjugated monoclonal anti-α-tubulin antibody (DM1A, Sigma) at a 1:100 dilution and propidium iodide (PI) at 37 ºC for 45 min. In Plk1 localization assay, the antibodies used were the mouse monoclonal antibody (mAb) anti-Plk1 (1:200; 35-306 aa; Abcam) and the Alexa Fluor 488-conjugated goat anti-mouse (1:1000; Invitrogen) antibody. DNA was stained with PI. Coverslips were washed with PBS, 50% glycerol was applied on the slide, and the coverslip was added on top with the cells facing the glycerol and sealed with glycerol. The stained cells were imaged by the confocal microscope (Leica, German) with a 63×objective.
Apoptosis assay HeLa cells (3×10
4 cells/well) were seeded onto 24-well plates and, after overnight incubation, the cells were incubated with Aristolactam AIIIa (10 µmol/L) for 24 h. The PARP cleavage assay was performed with equal amounts of total cellular proteins that were resolved on a 10%-SDS-polyacrylamide gel, and Western blotting analysis was performed using anti-PARP antibodies (BD Biosciences).
In Annexin V apoptosis assay, HeLa cells were seeded onto six-well plates and after overnight incubation, cells were incubated with Aristolactam AIIIa (10 µmol/L) for 24 h. Cells were trypsinized and incubated with Annexin V according to the manufacturer's recommendations (Calbiochem).
Surface plasmon resonance (SPR) technology-based binding assay
The binding of Aristolactam AIIIa to the PBD or CD was analyzed by SPR technology-based Biacore 3000 instrument (Biacore AB, Uppsala, Sweden). All experiments were carried out using HBS-EP (10 mmol/L HEPES pH 7.4, 150 mmol/L NaCl, 3.4 mmol/L EDTA and 0.005% surfactant P20) as running buffer with a constant flow rate of 30 µL/min at 25 °C. The PBD protein, which was diluted in 10 mmol/L sodium acetate buffer (pH 4.2) to a final concentration of 2 µmol/L, was covalently immobilized on the hydrophilic carboxymethylated dextran matrix of the CM5 sensor chip (BIAcore) using standard primary amine coupling procedure. The CD protein, which was diluted in 10 mmol/L sodium acetate buffer (pH 4.13) to a final concentration of 2 µmol/L, was immobilized on the chip using the same procedure. Aristolactam AIIIa was dissolved in the running buffer at different concentrations ranging from 1 to 10 µmol/L. All data were analyzed by BIAevaluation software, and the sensorgrams were processed by automatic correction for nonspecific bulk refractive index effects. The kinetic analyses of the Aristolactam AIIIa/PBD binding were performed based on the steady state affinity fit model according to the procedures described in the software manual, and the Aristolactam AIIIa/CD binding equilibrium dissociation constant was calculated based on the 1:1 Langmuir binding fit model.
To investigate the effect of Aristolactam AIIIa on the PBD/ CD interaction, the purified CD protein was immobilized on a CM5 sensor chip. After the PBD (14 µmol/L) was incubated with different concentrations of Aristolactam AIIIa (0, 24, 34.3, 49, 70, and 100 µmol/L) for 1 h, the samples were applied to the sensor chip at a flow rate of 10 µL/min for 60 s, followed by washing with HBS-EP 180 s. The binding ability of PBD towards the CD was reflected by RUs values recorded directly by the Biacore 3000 instrument. , and transformations were performed according to the manufacturer's protocol. First, 500 ng of plasmid DNA was added to 50 µL of competent cells and mixed with 36 µL of 1 mol/L lithium acetate, 5 µL of boiled 10 mg/mL ss-carrier DNA and 240 µL of 50% poly(ethylene glycol) (MW3350) at 30 ºC for 30 min followed by heat-shock at 42 ºC for 30 min and subsequently spread on a drop-out-agar plate that lacked leucine and tryptophan. The plates were incubated at 30 ºC for 48 h to allow for yeast growth. PCR was used to confirm the transformation of the target plasmids. A positive clone was inoculated into SD medium lacking leucine and tryptophan (SD-LT) overnight, the culture was then diluted to OD600 of 0.003 with SD medium lacking leucine, tryptophan, and histidine (SD-LTH) which was supplemented with 2 mmol/L of 3-amino-10,20,40-triazole (SD-LTH+3-AT) and 100 µmol/L of Aristolactam AIIIa. The medium was shaken at 250 r/min at 30 ºC for 48 h before 200 µL of the culture was added to the well of a 96-well microplate. The absorbance at 600 nm of the culture in the 96-well microplate was then measured by a Benchmark Plus TM microplate spectrophotometer (BIO-RAD). This is an alternative method based on the growth curve analysis for yeast culture that is amenable to a microtiter plate format. It is reproducible and of equal or greater sensitivity compared with the β-galactosidase assay [26] . All the yeast media were prepared according to the standard Protocols Handbook (PT3024-1, Clontech).
Results
Aristolactam AIIIa inhibits Plk1 activity
To evaluate the inhibition of Aristolactam AIIIa against Plk1, the Polo-like kinase1 Assay/Inhibitor Screening Kit (Cyclex Co, Japan) was used. During the assay, 1.25 munits of recombinant Plk1 (Cyclex Co, Japan) was mixed with different concentrations of either Aristolactam AIIIa or DMSO (as a control), and the kinase activity was measured by using Protein-X as substrate. As indicated in Figure 1B , the natural product Aristolactam AIIIa exhibited a dose-dependent inhibition against Plk1-mediated phosphorylation of Protein-X with an IC 50 value of 47.5 µmol/L.
In order to further confirm the inhibition of Aristolactam AIIIa against Plk1, the kinase activity of endogenous Plk1 immunoprecipitated from Nocodazole-arrested HeLa cells was measured after incubation with Aristolactam AIIIa (10 µmol/L and 100 µmol/L) or DMSO (as a control). As shown in Figure 1C , Aristolactam AIIIa also inhibited the endogenous Plk1 activity in a dose-dependent manner.
To investigate the potential selectivity of Aristolactam AIIIa against Plks, the inhibition of Aristolactam AIIIa against Figure 1D , Aristolactam AIIIa exhibited a dose-dependent inhibition against Plk3, indicating that Aristolactam AIIIa had no selectivity for Plks.
Aristolactam AIIIa inhibits the proliferation of human HeLa, A549, HGC, and HCT-8/V cells As has been reported [24] , some Aristolactam derivatives could exhibit cytotoxicity against KB, P388, A549, HT29, HL60, HeLa, and L1210 cells, but no detailed inhibition mechanism was investigated. Although Aristolactam AIIIa has been reported to inhibit platelet aggregation induced by collagen and AA, its anti-tumor activity has not yet been elucidated [27] . Here, the anti-proliferation effect of Aristolactam AIIIa on HeLa, A549, and HGC cancer cell lines was examined. As shown in Table  1 and Figure 2A , Aristolactam AIIIa inhibited the proliferation of these cancer cells in a dose-dependent manner with IC 50 values ranging from 7 to 30 µmol/L. Moreover, to further explore the potential inhibition of Aristolactam AIIIa against the relevant clinical drug-resistant cancer cell, the Navelbine (NVB)-resistant HCT-8/V cell line was assayed. As indicated in Figure 2B and Table 2 , Aristolactam AIIIa exhibited dosedependent inhibitory effects on HCT-8/V with an IC 50 of 3.55 µmol/L, even while 10 µmol/L of NVB had no effect on HCT-8/V proliferation.
Aristolactam AIIIa induces cell cycle arrest in the G 2 /M phase with spindle abnormalities in HeLa cells Plk1 was shown to be essential to mitotic progression and cytokinesis, and functional down-regulation of Plk1 (either by microinjecting Plk1-specific antibodies or overexpressing dominant-negative Plk1) might induce G 2 /M arrest [8, 28] . With these facts in mind, we thereby investigated the potential effect of Aristolactam AIIIa on the cell cycle of tumor cells. As shown in Figure 2C , incubation of HeLa cells with 10 µmol/L of Aristolactam AIIIa for 24 h increased the cell population staying in G 2 /M phase by 100% compared with the control cells, which thus suggested that Aristolactam AIIIa was able to induce cell cycle arrest at the G 2 /M phase. To further confirm this result, the cell cycle distribution pattern of HeLa cells treated for 48 h with Aristolactam AIIIa or DMSO was also investigated. As shown in Figure S1 , similar to the case in 24 h incubation, a 48 h incubation with Aristolactam AIIIa could also induce cell cycle arrest in G 2 /M phase.
It has been known that Plk1 is involved in bipolar spindle formation which requires proper spindle assembly. Cells injected with anti-Plkl antibodies display striking defects in their ability to assemble bipolar spindles, as manifested by the lack of focused spindle poles and unstable attachment of the chromosomes to the spindles [8, 29] . To test whether Aristolactam AIIIa could affect spindle assembly, we used confocal laser microscopy to image the spindle apparatus and chromosomes of Aristolactam AIIIa-treated cells. HeLa cells were incubated with either DMSO (as a control) or 10 µmol/ L of Aristolactam AIIIa for 12 h, fixed with 4% paraformaldehyde, and then stained with FITC conjugated anti-α-tubulin antibody (to visualize tubulin spindles) and propidium iodide Figure 2D and 2E) . Such results were in agreement with the previous results for Plk1-depleted cells [29] , and suggested that Aristolactam AIIIa could induce aberrant spindle assembly in cells through its inhibition against Plk1.
Aristolactam AIIIa induces apoptosis of cancer cells
Considering that the activation of apoptotic pathways could be detected by examining PARP (Poly [ADP-ribose] polymerase-1) cleavage [30] , a marker for caspase activation, we thereby examined the potential effects of Aristolactam AIIIa on the apoptosis of HeLa cells by determining the induction of the cleaved PARP p85 fragment. Western blot analysis showed PARP cleavage in Aristolactam AIIIa-treated HeLa cells ( Figure 3A) , indicating the apoptosis induction in these cells. This result is consistent with the reported effects of Plk1 siRNA [31] and other Plk1 inhibitors on cancer cells [20, 32] . To further confirm the above results, Aristolactam AIIIa (10 µmol/L) or DMSO-treated HeLa cells were labeled with Moreover, this phenomenon was also confirmed by the analysis of the cell cycle distribution pattern of HeLa cells with 24 h incubation of Aristolactam AIIIa. As shown in Figure 2C , the population of sub-G 0 /G 1 peaks were 3.67% (DMSO) and 8.85% (Aristolactam AIIIa 10 µmol/L), respectively, indicating Aristolactam AIIIa could induce apoptosis of cancer cells.
Aristolactam AIIIa binds to the catalytic domain of Plk1 and inhibits its activity
In order to further scrutinize the possible inhibition mechanism of Aristolactam AIIIa against Plk1, the binding and inhibition features of Aristolactam AIIIa against the Plk1 PBD and CD domains were characterized. SPR technology-based Biacore 3000 instrument was used to carry out the kinetic analysis of Aristolactam AIIIa binding to the CD. In the assay, the 1:1 Langmuir binding fit model was used to determine the equilibrium dissociation constant (K D ), and the accuracy of the obtained results was evaluated by χ 2 . As indicated in Figure 4A and Table 3 , Aristolactam AIIIa To test the enzymatic inhibition of Aristolactam AIIIa against the CD, we conducted a similar kinase inhibition assay against the purified recombinant CD (residues 1-370 of Plk1). During the assay, after incubation of the CD with DMSO (as a control) or Aristolactam AIIIa (100 µmol/L and 10 µmol/ L), the kinase activity was measured as described above. As indicated in Figure 4B , Aristolactam AIIIa exhibited a dosedependent inhibition against the CD. To further confirm this inhibition, the kinase activity of the CD immunoprecipitated from the CD transient transfected 293T cells was also measured as incubated with Aristolactam AIIIa (100 µmol/L) or DMSO (as a control). The results listed in Figure 4C have thereby validated the Aristolactam AIIIa inhibition against the CD.
Taken together, the above results have suggested that Aristolactam AIIIa could directly bind the catalytic domain of Plk1 and inhibit its activity.
Aristolactam AIIIa targets the PBD and increases the PBD/CD interaction
The auto-inhibitory mechanism of Plk1 by its intrinsic Polo box domain (PBD) has made the PBD as another potential target besides the catalytic domain. To investigate whether Aristolactam AIIIa could interfere with PBD function through its binding to the PBD, the binding affinity of Aristolactam AIIIa against PBD was studied by using the SPR technology-based Biacore 3000 instrument. In the assay, immobilization of the PBD on the Biacore biosensor chip resulted in a resonance signal of 7540 resonance units (RUs). The results in Figure 5A indicated the dose-dependent biosensor RUs for Aristolactam AIIIa, suggesting that this natural product could bind to the PBD in vitro. The steady state affinity fit model was used to determine the equilibrium dissociation constant K D , and the In addition, cell-based assay was also carried out to further examine the potential targeting of Aristolactam AIIIa against the PBD in the PBD over-expressing HeLa cells. After transient transfection with pCDNA3.1a-PBD, HeLa cells were incubated with Aristolactam AIIIa at 10 µmol/L for 48 h. As shown in Figure 5B , Aristolactam AIIIa could exhibit inhibitory effects by 50% on the proliferation of the PBD overexpression in HeLa cells in the SRB assay. Compared with the 71% inhibition by Aristolactam AIIIa against the proliferation of the HeLa cells transfected with empty vector (Figure 5B) , the result supports the finding that Aristolactam AIIIa targets the PBD.
Since the PBD plays a critical role in Plk subcellular localization [33] and Aristolactam AIIIa has been suggested to target the PBD as mentioned above, the localization of endogenous Plk1 in Aristolactam AIIIa or DMSO-treated HeLa cells was thereby examined by using an antibody directed against the N terminus of Plk1 (35-206 aa). As indicated in Figure 5C , in Aristolactam AIIIa-treated cells at mitosis phase, endogenous Plk1 was detected on spindle poles and concentrated close to the midbody in the postmitotic bridges connecting the dividing cells, which is consistent with the founded in DMSO-treated cells.
As has been reported, the PBD is believed to regulate Plk1 activity through its intramolecular interaction with the catalytic domain (CD) [16, 17] . Considering this fact, we have thus inspected the potential influence of Aristolactam AIIIa on the PBD/CD interaction by yeast two-hybrid system and SPR technology. In the yeast two-hybrid assay, the yeast cells transformed with both PBD and CD were incubated with either 100 µmol/L Aristolactam AIIIa or DMSO (as a control) for 48 h. The result in Figure 6A implied that Aristolactam AIIIa increased the PBD binding to the catalytic domain of Plk1 by ~43%. Additionally, such Aristolactam AIIIa-stimulated PBD/CD interaction was also confirmed in vitro by SPR technology-based assay ( Figure 6B) .
Summarily, all the above results indicated that Aristolactam AIIIa targets both the PBD and CD. It interferes with the PBD function through the inhibition of Plk kinase activity by increasing the PBD/CD interaction without affecting Plk1 localization to the proper subcellular substructure.
Discussion
Plk1 plays essential roles in numerous aspects of mitotic progression. A number of studies have demonstrated that Plk1 is over-expressed in a broad spectrum of human tumors [12] , and Plk1 has been determined as an attractive target for cancer therapy. To date, three kinds of small molecular inhibitors of Plk1 have been discovered: ATP competitive inhibitor, substrate competitive inhibitor and the PBD inhibitor.
In general, the ATP-binding domain is a regular target for protein kinase inhibitor discovery. However, specificity of such target-based inhibitor is difficult to obtain due to the high degree of structural conservation among ATP-binding pockets, and only a few ATP-like inhibitors of Plk1 have so far been published. The first small molecule Plk1 inhibitor was scytonemin, a non-specific ATP competitor, which exhibited comparable potencies against other Ser/Thr and Thr/Tyr kinases including MYT1, CHK1, CDK1, and PKC [18, 19] . Exploration of Plk1 non-ATP competitor is another choice for a Plk1 specific inhibitor in anti-tumor drug discovery. For example, the pharmacophore ON01910 was reported to be a substrate-competitive inhibitor of recombinant casein and CDC25C [20] . Another strategy in the development of Plk1 specific inhibitor is to target the PBD, which has a critical role in the regulation of the kinase activity and the subcellular localization of Plk1 [16] . Recently, the first small molecule targeting the PBD was reported, which could interfere with Plk1 intracellular localization by inhibiting the function of the PBD [21] . Aristolactams are phenanthrene lactam alkaloids that are structurally and biogenetically related to aporphines, which have been reported to show inhibitory activity against cancer cell proliferation; however, the relevant detailed data still remain unclear [23, 24] . As a member of Aristolactams, Aristolactam AIIIa demonstrated significant inhibition of platelet npg aggregation induced by collagen and AA [27] , while its antitumor activity has not yet been elucidated. By random screening against the in-house natural product library, we discovered that Aristolactam AIIIa functions as a new type of ligand targeting the PBD, as investigated by the SPR and enzymatic inhibition assays. It could inhibit the proliferation of HeLa, A549, HGC, and HCT-8/V cells, influence cell cycle progression and spindle assembly in HeLa cells and induce the apoptosis in HeLa cells.
Enzymatic characterization indicated that Aristolactam AIIIa could exhibit inhibition activity against the CD, which might contribute to its inhibition against the full length Plk1 in vitro, similar to previously published inhibitors [20, 32] . To further investigate the potential inhibition mechanism of Aristolactam AIIIa against Plk1, the kinetic feature of Aristolactam AIIIa binding to the PBD was assayed. SPR results demonstrated a strong binding affinity of Aristolactam AIIIa to the PBD (K D =2.99 µmol/L). Since the PBD has a critical role in the regulation Plk's kinase activity by interacting with the catalytic domain of Plk1 [16, 17] , the result that Aristolactam AIIIa could enhance the PBD interaction with the CD as indicated by SPR and yeast two-hybrid-based assays has shown that this natural product further strengthened the self-regulatory effect of the PBD on Plk1.
It is noticed that the small molecule inhibitors reported by Reindl et al [21] inhibited the function of the Plk1 PBD and interfered with the intracellular localization of Plk1, while Aristolactam AIIIa did not affect the localization of Plk1. Such discrepancy might possibly come from the different PBD binding sites for the compounds. The reported inhibitors [21] interfered with the interaction between PBD and its intracellular anchoring sites of the substrates, resulting in mis-localization of Plk1. However, Aristolactam AIIIa enhanced the CD/PBD interaction, thereby inhibiting Plk1 activity without affecting Plk1 localization. All these findings thus revealed that the regulation of PBD in Plk1's kinase activity and the subcellular localization of Plk1 are closely related to the PBD binding sites.
In summary, we have identified the Aristolactam derivative, Aristolactam AIIIa as a new type of ligand targeting the PBD by random screening our in-house natural product library. Cell-based assays indicated that this natural product could inhibit the proliferation of HeLa, A549, HGC, and HCT-8/V cells, induce mitotic arrest at the G 2 /M phase with spindle abnormalities and promote apoptosis. Different from the published Plk1 inhibitors, Aristolactam AIIIa could bind to the interaction interface of CD/PBD due to targets both the catalytic domain and the polo-box domain of Plk1 kinase, and enhances the CD/PBD interaction. Our current work is expected to shed light on the potential antitumor mechanism of Aristolactam AIIIa, and this determined Plk1 inhibitor may also be used as a lead compound for further research. 
